TELAML1positive

TEL-AML1 positive describes the presence of the TEL-AML1 fusion gene in leukemic cells, usually due to the chromosomal translocation t(12;21)(p13;q22). The fusion joins the TEL (ETV6) gene on chromosome 12 with RUNX1 (AML1) on chromosome 21, creating a chimeric transcription factor that interferes with normal blood cell development and contributes to leukemogenesis, particularly in B-cell precursor acute lymphoblastic leukemia (B-ALL). The fusion is believed to arise prenatally in many cases.

Detection of TEL-AML1 status is typically achieved by molecular assays such as RT-PCR or fluorescence in situ hybridization (FISH) on diagnostic bone marrow or peripheral blood samples. TEL-AML1 positivity may be used for risk stratification and for monitoring minimal residual disease (MRD) during treatment using patient-specific primers or probes.

Clinically, TEL-AML1 positive B-ALL is associated with a favorable prognosis in children treated with modern regimens, with higher event-free survival and overall survival, particularly when MRD is low or negative after induction. The prognosis is more variable in adults and in higher-risk disease; relapse can occur, and outcome depends on MRD response and treatment intensity.

Epidemiologically, TEL-AML1 occurs in a substantial minority of pediatric B-ALL patients, estimated around 20-25%, and is less common in infants and adults. Treatment relies on standard multi-agent chemotherapy with MRD-guided risk adaptation, though there are no therapies specifically targeting TEL-AML1. Understanding its biology informs prognosis and ongoing research into leukemogenesis and clonal evolution.

Notes indicate that TEL-AML1 can be present in pre-leukemic hematopoietic stem cells in some healthy individuals, suggesting prenatal origin and potential clonal evolution; the term TEL-AML1 positive is used in clinical and research contexts for diagnostic and prognostic purposes.